A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015..
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on.
The market was a low volume chop fest (although with a fairly narrow range) for the most part and I do not think we should read too much into price.
Cubist management gave a five-year outlook at their Investor Day presentation on June 11; it was quite impressive. The most notable point was management’s projection of $2 billion in global.
CBST: 2011 Q4 Quarterly Report Follow-up; Catalysts Through 2012 and Beyond Thursday, January 19 Cubist announced fourth quarter and full-year 2011 results today that surpassed analyst expectations. Excluding one-time costs,.
CBST: Initiating Coverage Overview: Cubist is a small commercial stage biotech focused on the development of acute care products. Its revenues are almost entirely derived from the antibiotic Cubicin, used.
The market is weak to open as a follow through on the selling yesterday. This feels like a reversal day but it is way too early to tell but either.
The market is pretty crappy to start this morning but let us see if the trend reverses. We have had a lot gap higher opens and then weakness the rest.
It was a neutral open for the market which is pretty positive given the selling related to the Ebola case in NYC. It is very positive to see the market.
The market is OK this morning with biotechs not the strongest sector. That is not completely unexpected given the 60 Minutes story on cancer drug pricing. As such you would.
It is not Tuesday so the selling continues. It seems like the turnaround Tuesdays happen but have no sticking power. At some point that trend will change and that should.
The rollercoaster continues as we swing up and down in seemingly ever tighter time frames. In some ways, that seems good in that base building is a messy process with.
It was a great day for biotechs despite a neutral to bearish macro drag. We not only had some great price action but we continued with the positive news. This.
Stocks were strong out of the gate and biotechs with them but the market weakened throughout the morning. Biotechs did not necessarily lead the market lower but seemed to be.
It was more of the same in the market (so to speak) and while there was some green out there, I am not convinced that we have completely consolidated that.